Results 131 to 140 of about 6,071 (199)

Improvement in Palivizumab Administration in Severely Immunocompromised Children: A Single-institution Quality Improvement Initiative. [PDF]

Pediatr Qual Saf
Hijano DR, Allen DC, Burlison J, Ross HS, Ferrolino JA, Dallas RH, Hayden RT, Morton TH, Greene WL, Wolf J, Ramilo O, Flynn PM, Cross SJ.   +12 more
europepmc   +1 more source

Prevalence of Resistance-Associated Mutations in RSV F Protein Against Monoclonal Antibodies Prior to Widespread Implementation: Findings From a Prospective German Pediatric Cohort. [PDF]

Influenza Other Respir Viruses
Wetzke M, Le DB, Tometten I, Ritter S, Lübke N, Timm J, Dilthey A, Panning M, Walker A, Happle C.   +9 more
europepmc   +1 more source

Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children. [PDF]

Clin Exp Pediatr
Choi SH, Kim DH, Ahn JG, Yun KW, Eun BW, Lee J, Lee J, Lee TJ, Lee H, Jo DS, Cho EY, Cho HK, Choe YJ, Choi UY, Kim YK, Committee on Infectious Diseases of the Korean Pediatric Society.   +15 more
europepmc   +1 more source

Complementary Strategy of Maternal Immunization with RSVpreF Vaccine and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment. [PDF]

Infect Dis Ther
Polistena B, Midulla F, Sotgiu G, d'Angela D, Di Virgilio R, Spandonaro F.   +5 more
europepmc   +1 more source

Nirsevimab in High-Risk Infants in a Respiratory Syncytial Virus Prevention Strategy.

JAMA Netw Open
Sauré D, Torres JP, Goic M, Thraves C, Pacheco J, Burgos J, Zgheib A, Del Solar F, Neira I, O'Ryan M, Basso LJ.   +10 more
europepmc   +1 more source

RSV vaccine development: advances and fusion protein-focused strategies. [PDF]

Front Immunol
Xu W, Katte RH, Lu M.
europepmc   +1 more source

Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration. [PDF]

J Infect Dis
Iglesias-Caballero M, Mas V, Campoy A, Calvo C, García ML, Alcolea S, Moreno-Parrado L, Reina J, Navascués A, Antón A, Davina-Nunez C, Perez-Castro S, Costa J, Fernández-González A, Lepe JA, Gaona C, Pérez Z, García-Martínez de Artola D, Vázquez-Morón S, Camarero S, Cano O, Pozo F, Casas I.   +22 more
europepmc   +1 more source

Epidemiological Impact of Nirsevimab on Admissions for Bronchiolitis in a Pediatric Emergency Department: A Single-Center Cohort Study. [PDF]

Viruses
Castagno E, Aschieri C, Ferri I, El Khbazi S, Milani L, Comoretto RI, Raffaldi I, Tardivo I, Spada M, Bondone C, Fagioli F.   +10 more
europepmc   +1 more source

iBody-mediated tuning of synthetic cytokine receptor activation via rational nanobody interface engineering. [PDF]

MAbs
Kunze R, Navratil F, Beichert J, Geyer F, Floss DM, Kolmar H, Scheller J, Pudewell S.   +7 more
europepmc   +1 more source

Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants' First RSV Season in the UK. [PDF]

Infect Dis Ther
Chetty M, Costello P, Yarnoff B, Musci R, Ghemmouri M.   +4 more
europepmc   +1 more source